X0306 4 2020-02-17 0 0000875320 VERTEX PHARMACEUTICALS INC / MA VRTX 0001242825 LEIDEN JEFFREY M C/O VERTEX PHARMACEUTICALS INCORPORATED 50 NORTHERN AVENUE BOSTON MA 02210 1 1 0 0 CEO & President Common Stock 2020-02-17 4 F 0 9314 241.50 D 123226 D Common Stock 2020-02-18 4 S 0 1680 241.78 D 121546 D Common Stock 2020-02-18 4 S 0 4241 242.61 D 117305 D Common Stock 2020-02-18 4 S 0 1971 243.65 D 115334 D Common Stock 2020-02-18 4 S 0 2030 244.87 D 113304 D Common Stock 2020-02-18 4 S 0 1763 245.66 D 111541 D Common Stock 440 I 401(k) Transaction made pursuant to Dr. Leiden's company approved trading plan under Rule 10b5-1. Open market sales reported on this line occurred at a weighted average price of $241.78 (range $241.20 to $242.19). Dr. Leiden undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price. Open market sales reported on this line occurred at a weighted average price of $242.61 (range $242.23 to $243.19). Open market sales reported on this line occurred at a weighted average price of $243.65 (range $243.24 to $244.23). Open market sales reported on this line occurred at a weighted average price of $244.87 (range $244.30 to $245.26). Open market sales reported on this line occurred at a weighted average price of $245.66 (range $245.32 to $245.92). /s/ Omar White, Attorney-in-Fact 2020-02-19